Alaunos Therapeutics (TCRT) Depreciation & Amortization (CF) (2009 - 2026)

Alaunos Therapeutics (TCRT) has 18 years of Depreciation & Amortization (CF) data on file, last reported at $8000.0 in Q1 2026.

• Quarterly Depreciation & Amortization (CF) changed N/A year-over-year to $8000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15000.0 (changed N/A YoY) and the FY2025 annual result came in at $7000.0, up 250.0% from the prior year.
• Depreciation & Amortization (CF) grew to $8000.0 in Q1 2026, from $7000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $699000.0 in Q2 2023 to a low of -$1000.0 in Q4 2024.
• A 5-year average of $391615.4 and a median of $679000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) tumbled 100.41% — and 2025, when it surged 800.0%.
• Tracing TCRT's Depreciation & Amortization (CF) over 5 years: stood at $694000.0 in 2022, then tumbled by 65.27% to $241000.0 in 2023, then plunged by 100.41% to -$1000.0 in 2024, then surged by 800.0% to $7000.0 in 2025, then increased by 14.29% to $8000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $8000.0 (Q1 2026), $7000.0 (Q4 2025), and -$1000.0 (Q4 2024), per Business Quant data.